MCID: ACT095
MIFTS: 32

Acute Biphenotypic Leukemia malady

Categories: Blood diseases, Rare diseases, Cancer diseases

Aliases & Classifications for Acute Biphenotypic Leukemia

Aliases & Descriptions for Acute Biphenotypic Leukemia:

Name: Acute Biphenotypic Leukemia 38 56 69

Classifications:



External Ids:

Orphanet 56 ORPHA98837
ICD10 via Orphanet 34 C95.0
MESH via Orphanet 43 D015456
UMLS via Orphanet 70 C0023464

Summaries for Acute Biphenotypic Leukemia

MalaCards based summary : Acute Biphenotypic Leukemia is related to acute leukemia of ambiguous lineage and leukemia. An important gene associated with Acute Biphenotypic Leukemia is KMT2A (Lysine Methyltransferase 2A), and among its related pathways/superpathways are Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers and Transcriptional misregulation in cancer. The drugs Methotrexate and Mycophenolate mofetil have been mentioned in the context of this disorder. Affiliated tissues include bone, myeloid and t cells, and related phenotype is Increased shRNA abundance (Z-score > 2).

Related Diseases for Acute Biphenotypic Leukemia

Diseases related to Acute Biphenotypic Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 36)
id Related Disease Score Top Affiliating Genes
1 acute leukemia of ambiguous lineage 11.2
2 leukemia 10.5
3 glycogen storage disease type 0 10.0 FLT3 KMT2A
4 acute necrotizing encephalopathy 10.0 KMT2A MPO
5 acute motor-sensory axonal neuropathy 10.0 FLT3 MPO
6 essential thrombocythemia 10.0
7 necrotic uveal melanoma 10.0 FLT3 MLLT10
8 nephrotic syndrome type 11 10.0 KMT2A MLLT10
9 lymphoblastic lymphoma 9.9
10 lymphoma 9.9
11 myeloid leukemia 9.9
12 bifid uvula 9.9 FLT3 MLLT10
13 peroxisome biogenesis disorder 7a 9.8 DNTT FLT3
14 desmoid tumor 9.8 DNTT MPO
15 actinobacillosis 9.8 FLT3 MPO
16 precursor t-cell acute lymphoblastic leukemia 9.8
17 multiple myeloma 9.8
18 aspergillosis 9.8
19 arthritis 9.8
20 lymphoblastic leukemia 9.8
21 sarcoma 9.8
22 pharyngitis 9.8
23 myeloid sarcoma 9.8
24 leukemia, acute myeloid 9.7 DNTT FLT3 KMT2A
25 lymphoma, small cleaved-cell, diffuse 9.7 DNTT KMT2A MPO
26 malignant testicular leydig cell tumor 9.7 DNTT FLT3 MPO
27 adult respiratory distress syndrome 9.7 FLT3 KMT2A MLLT10 MPO
28 hemophagocytic lymphohistiocytosis 9.6 DNTT FLT3 KMT2A MLLT10
29 adducted thumbs dundar type 9.5 DNTT FLT3 KMT2A MPO
30 neurofibromatosis 9.5 DNTT FLT3 KMT2A MPO
31 hyperphosphatasia with mental retardation syndrome 2 9.5 DNTT FLT3 KMT2A MPO
32 bleeding disorder, platelet-type, 18 9.5 DNTT FLT3 KMT2A MPO
33 acute leukemia 9.3 DNTT FLT3 KMT2A MLLT10 MPO
34 acute lymphocytic leukemia 9.3 DNTT FLT3 KMT2A MLLT10 MPO
35 phosphoserine phosphatase deficiency 9.3 DNTT FLT3 KMT2A MLLT10 MPO
36 cranioectodermal dysplasia 1 9.3 DNTT FLT3 KMT2A MLLT10 MPO

Graphical network of the top 20 diseases related to Acute Biphenotypic Leukemia:



Diseases related to Acute Biphenotypic Leukemia

Symptoms & Phenotypes for Acute Biphenotypic Leukemia

GenomeRNAi Phenotypes related to Acute Biphenotypic Leukemia according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 10.07 MPO
2 Increased shRNA abundance (Z-score > 2) GR00366-A-102 10.07 DNTT FLT3
3 Increased shRNA abundance (Z-score > 2) GR00366-A-115 10.07 FLT3
4 Increased shRNA abundance (Z-score > 2) GR00366-A-120 10.07 FLT3
5 Increased shRNA abundance (Z-score > 2) GR00366-A-121 10.07 FLT3
6 Increased shRNA abundance (Z-score > 2) GR00366-A-122 10.07 FLT3
7 Increased shRNA abundance (Z-score > 2) GR00366-A-123 10.07 DNTT FLT3
8 Increased shRNA abundance (Z-score > 2) GR00366-A-126 10.07 MPO
9 Increased shRNA abundance (Z-score > 2) GR00366-A-138 10.07 DNTT
10 Increased shRNA abundance (Z-score > 2) GR00366-A-151 10.07 DNTT
11 Increased shRNA abundance (Z-score > 2) GR00366-A-157 10.07 DNTT MPO
12 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.07 DNTT
13 Increased shRNA abundance (Z-score > 2) GR00366-A-163 10.07 FLT3
14 Increased shRNA abundance (Z-score > 2) GR00366-A-176 10.07 MPO
15 Increased shRNA abundance (Z-score > 2) GR00366-A-182 10.07 DNTT
16 Increased shRNA abundance (Z-score > 2) GR00366-A-186 10.07 MPO
17 Increased shRNA abundance (Z-score > 2) GR00366-A-197 10.07 DNTT
18 Increased shRNA abundance (Z-score > 2) GR00366-A-25 10.07 FLT3
19 Increased shRNA abundance (Z-score > 2) GR00366-A-29 10.07 MPO
20 Increased shRNA abundance (Z-score > 2) GR00366-A-36 10.07 MPO
21 Increased shRNA abundance (Z-score > 2) GR00366-A-57 10.07 MPO
22 Increased shRNA abundance (Z-score > 2) GR00366-A-7 10.07 MPO
23 Increased shRNA abundance (Z-score > 2) GR00366-A-70 10.07 MPO FLT3
24 Increased shRNA abundance (Z-score > 2) GR00366-A-73 10.07 DNTT

Drugs & Therapeutics for Acute Biphenotypic Leukemia

Drugs for Acute Biphenotypic Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 170)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methotrexate Approved Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
2
Mycophenolate mofetil Approved, Investigational Phase 3,Phase 2 128794-94-5 5281078
3
Mycophenolic acid Approved Phase 3,Phase 2 24280-93-1 446541
4
Tacrolimus Approved, Investigational Phase 3,Phase 2 104987-11-3 445643 439492
5
Benzocaine Approved Phase 3,Phase 2 1994-09-7, 94-09-7 2337
6
Triamcinolone Approved, Vet_approved Phase 3,Phase 2 124-94-7 31307
7
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
8
Ofloxacin Approved Phase 3 82419-36-1 4583
9
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 1,Phase 2 59-30-3 6037
10
leucovorin Approved, Nutraceutical Phase 3,Phase 1,Phase 2 58-05-9 54575, 6560146 143
11 tannic acid Approved, Nutraceutical Phase 3,Phase 2
12 Antilymphocyte Serum Phase 3,Phase 2,Phase 1
13 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
14 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
15 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
16 Antimetabolites Phase 3,Phase 2,Phase 1
17 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
18 Antirheumatic Agents Phase 3,Phase 2,Phase 1
19 Calcineurin Inhibitors Phase 3,Phase 2
20 Dermatologic Agents Phase 3,Phase 1,Phase 2
21 Folic Acid Antagonists Phase 3,Phase 1,Phase 2
22 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 1,Phase 2
23 Vitamin B Complex Phase 3,Phase 1,Phase 2
24 Anti-Infective Agents Phase 3,Phase 1,Phase 2
25 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
26 triamcinolone acetonide Phase 3,Phase 2
27 Triamcinolone diacetate Phase 3,Phase 2
28 Triamcinolone hexacetonide Phase 3,Phase 2
29 Cytochrome P-450 CYP1A2 Inhibitors Phase 3
30 Cytochrome P-450 Enzyme Inhibitors Phase 3
31 Renal Agents Phase 3
32 Folate Nutraceutical Phase 3,Phase 1,Phase 2
33 Vitamin B9 Nutraceutical Phase 3,Phase 1,Phase 2
34
Abatacept Approved Phase 2 332348-12-6 10237
35
Cyclosporine Approved, Investigational, Vet_approved Phase 2 79217-60-0, 59865-13-3 5284373 6435893
36
Busulfan Approved, Investigational Phase 2,Phase 1 55-98-1 2478
37
Cytarabine Approved, Investigational Phase 1, Phase 2 147-94-4 6253
38
Cyclophosphamide Approved, Investigational Phase 2,Phase 1 50-18-0, 6055-19-2 2907
39
Vincristine Approved, Investigational Phase 2,Phase 1 2068-78-2, 57-22-7 5978
40
Mitoxantrone Approved, Investigational Phase 1, Phase 2 65271-80-9 4212
41
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
42
Melphalan Approved Phase 2,Phase 1 148-82-3 4053 460612
43
Asparaginase Approved Phase 2 9015-68-3
44
Hydrocortisone Approved, Vet_approved Phase 2,Phase 1 50-23-7 5754 657311
45
Pegaspargase Approved, Investigational Phase 2 130167-69-0
46
Clofarabine Approved, Investigational Phase 2,Phase 1 123318-82-1 119182
47
Fludarabine Approved Phase 1, Phase 2 21679-14-1, 75607-67-9 30751
48
Vidarabine Approved Phase 1, Phase 2 24356-66-9 32326 21704
49
Sorafenib Approved, Investigational Phase 1, Phase 2 284461-73-0 216239 406563
50
Dexamethasone Approved, Investigational, Vet_approved Phase 2,Phase 1 50-02-2 5743

Interventional clinical trials:

(show top 50) (show all 52)
id Name Status NCT ID Phase
1 Thymoglobulin in Unrelated Hematopoietic Progenitor Cell Transplantation Unknown status NCT01217723 Phase 3
2 Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention Recruiting NCT01951885 Phase 3
3 Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation Active, not recruiting NCT01371656 Phase 3
4 Safety and Tolerability Trial of Abatacept-based Immunosuppression for Prevention of Acute Graft Versus Host Disease (aGVHD) During Transplant Unknown status NCT01012492 Phase 2
5 Busulfan Plus Clofarabine Followed by Allogeneic Hematopoietic Stem Cell Transplantation Completed NCT00990249 Phase 2
6 Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia Completed NCT00372619 Phase 1, Phase 2
7 A Study of Withdrawal of Immunosuppression and Donor Lymphocyte Infusions Following Allogeneic Transplant for Pediatric Hematologic Malignancies Completed NCT01036009 Phase 2
8 Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor Completed NCT01350245 Phase 2
9 A Phase 2 Study of Clofarabine, Idarubicin, Cytarabine, Vincristine, and Corticosteroids - Mixed Phenotype Acute Leukemia (MPAL) Recruiting NCT02135874 Phase 2
10 Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib Tosylate in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Recruiting NCT02728050 Phase 1, Phase 2
11 GVHD Prophylaxis With Post-transplantation Bendamustine in Refractory Leukemia Recruiting NCT02799147 Phase 1, Phase 2
12 Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes Recruiting NCT02044796 Phase 1, Phase 2
13 Donor Umbilical Cord Blood Transplant With or Without Ex-vivo Expanded Cord Blood Progenitor Cells in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, or Myelodysplastic Syndromes Recruiting NCT01690520 Phase 2
14 Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD Recruiting NCT02220985 Phase 2
15 Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematologic Disease Recruiting NCT00719888 Phase 2
16 Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Recruiting NCT01028716 Phase 2
17 Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematological Cancer Who Are Undergoing Umbilical Cord Blood Transplant Recruiting NCT00796068 Phase 2
18 HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide Recruiting NCT02793544 Phase 2
19 Cladribine Plus Idarubicin Plus Cytarabine (ARAC) in Patients With Acute Myeloid Leukemia (AML), High Risk Myelodysplastic Syndrome (HR MDS) or Myeloid Blast Phase of Chronic Myeloid Leukemia (CML) Recruiting NCT02115295 Phase 2
20 Phase II Trial of Myeloablative Conditioning & Transplantation of Partially HLA-mismatched Marrow With Post-transplant Cyclophosphamide for Peds Pts w/ Hematologic Malignancies Recruiting NCT02120157 Phase 2
21 UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep Recruiting NCT02722668 Phase 2
22 Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haploidentical Related Hematopoietic Recruiting NCT02988466 Phase 2
23 Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in Children Active, not recruiting NCT01858740 Phase 2
24 Phase II Study of Fludarabine, Cytarabine (ARA-C) and Erwinase IV in Patients With Relapsed or Refractory Hematologic Malignancies Not yet recruiting NCT02718755 Phase 2
25 Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer Suspended NCT00723099 Phase 2
26 Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies Terminated NCT02419755 Phase 2
27 Prophylactic White Cell Transfusions Versus Therapeutic White Cell Transfusions in Patients With Leukemia Terminated NCT01204788 Phase 2
28 Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome Completed NCT02212561 Phase 1
29 Entinostat and Clofarabine in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Poor-Risk Acute Lymphoblastic Leukemia or Bilineage/Biphenotypic Leukemia Completed NCT01132573 Phase 1
30 AT9283 in Treating Young Patients With Relapsed or Refractory Acute Leukemia Completed NCT01431664 Phase 1
31 MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia Completed NCT01231919 Phase 1
32 Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematologic Malignancies Completed NCT00908167 Phase 1
33 Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia Recruiting NCT02879695 Phase 1
34 S1312, Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Leukemia Recruiting NCT01925131 Phase 1
35 Decitabine, Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Recruiting NCT02921061 Phase 1
36 Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML Recruiting NCT02091245 Phase 1
37 Crenolanib in Combination With Sorafenib in Patients With Refractory or Relapsed Hematologic Malignancies Active, not recruiting NCT02270788 Phase 1
38 POETIC Plerixafor as a Chemosensitizing Agent for Relapsed Acute Leukemia and MDS in Pediatric Patients Active, not recruiting NCT01319864 Phase 1
39 Infusion of Allogeneic Umbilical Cord Blood-Derived CD19-Specific T Cells Active, not recruiting NCT01362452 Phase 1
40 Infusion of Allogeneic CD19-Specific T Cells From Peripheral Blood Active, not recruiting NCT01497184 Phase 1
41 Standard Maintenance POMP/D Plus Ixazomib Maintenance Therapy in Adult Patients With Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma or Mixed Phenotype Acute Leukemia in Complete Remission (CR) Not yet recruiting NCT02578511 Phase 1
42 Phase I Study Of Vincristine, Doxorubicin, And Dexamethasone (VXD) Plus Ixazomib In Adults With Relapsed Or Refractory Acute Lymphoblastic Leukemia/Lymphoma, Lymphoblastic Lymphoma Or Mixed Phenotype Acute Leukemia Terminated NCT01887587 Phase 1
43 Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia Terminated NCT00933985 Phase 1
44 Infusion of Allogeneic, 3rd Party CD19-specific T Cells Withdrawn NCT02274506 Phase 1
45 Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia Unknown status NCT00550992
46 Pilot Study of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic Malignancies Completed NCT00013533 Early Phase 1
47 Structural Imaging and Cognitive Functions in Adult Stem Cell Transplant Recipients Treated With Chemotherapy Alone or in Combination With Radiotherapy Completed NCT00606216
48 Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement Recruiting NCT02828358
49 High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia Recruiting NCT02551718
50 Laboratory-Treated Donor Cord Blood Cell Infusion Following Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia Active, not recruiting NCT01701323

Search NIH Clinical Center for Acute Biphenotypic Leukemia

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Acute Biphenotypic Leukemia cell therapies at LifeMap Discovery.

Genetic Tests for Acute Biphenotypic Leukemia

Anatomical Context for Acute Biphenotypic Leukemia

MalaCards organs/tissues related to Acute Biphenotypic Leukemia:

39
Bone, Myeloid, T Cells, Monocytes

Publications for Acute Biphenotypic Leukemia

Articles related to Acute Biphenotypic Leukemia:

(show all 25)
id Title Authors Year
1
Concomitant transformation of monoclonal gammopathy of undetermined significance to multiple myeloma and of essential thrombocythemia to acute biphenotypic leukemia 37 years after initial diagnosis. ( 24086946 )
2013
2
Lateral pharyngeal wall myeloid sarcoma as a relapse of acute biphenotypic leukemia: a case report and review of the literature. ( 24377982 )
2013
3
Activation of a novel palmitoyltransferase ZDHHC14 in acute biphenotypic leukemia and subsets of acute myeloid leukemia. ( 21151021 )
2011
4
Cryptic insertion into 11q23 of MLLT10 not involved in t(1;15;11;10)(p36;q11;q23;q24) in infant acute biphenotypic leukemia. ( 19380030 )
2009
5
Essential thrombocythemia transforming into acute biphenotypic leukemia in a patient on hydroxyurea monotherapy. ( 19752004 )
2009
6
Successful voriconazole treatment of invasive pulmonary aspergillosis in a patient with acute biphenotypic leukemia. ( 19727206 )
2009
7
Precursor T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma and acute biphenotypic leukemias. ( 17369128 )
2007
8
Nelarabine activity in acute biphenotypic leukemia. ( 17512588 )
2007
9
Arthritis preceding acute biphenotypic leukemia. ( 16220224 )
2006
10
Acute biphenotypic leukemia arising in a patient with essential thrombocythemia. ( 16823822 )
2006
11
Bridging necrosis and reticulin bridging fibrosis induced by intrahepatic involvement of acute biphenotypic leukemia. ( 17207092 )
2006
12
Acute biphenotypic leukemia and an acquired X chromosome. ( 15676158 )
2005
13
Trisomy 4 as the sole karyotypic abnormality in a case of acute biphenotypic leukemia with T-lineage markers in minimally differentiated acute myelocytic leukemia. ( 15041226 )
2004
14
Successful treatment of massive gastrointestinal hemorrhage in acute biphenotypic leukemia with recombinant factor VIIa (NovoSeven). ( 15060424 )
2004
15
Simultaneous novel BCR-ABL gene mutation and increased expression of BCR-ABL mRNA caused clinical resistance to STI571 in double-Ph-positive acute biphenotypic leukemia. ( 12953816 )
2003
16
Acute biphenotypic leukemia in the adults. ( 12408768 )
2002
17
Establishment of a cell line with variant BCR/ABL breakpoint expressing P180BCR/ABL from late-appearing Philadelphia-positive acute biphenotypic leukemia. ( 9790503 )
1998
18
Definition of acute biphenotypic leukemia. ( 9107085 )
1997
19
Trisomy 4 as the sole karyotypic anomaly in acute biphenotypic leukemia with B lineage markers and in acute minimally differentiated myeloid leukemia (M0). ( 7697636 )
1995
20
An adult case of acute biphenotypic leukemia with characteristic mixed morphology. ( 8232165 )
1993
21
Chromosome 21 rearrangement in acute biphenotypic leukemia. ( 1360869 )
1992
22
Surface marker analysis and karyotype distinguish acute biphenotypic leukemia from acute myelogenous leukemia expressing terminal deoxynucleotidyl transferase. ( 1913454 )
1991
23
Trisomy 4 in a case of acute biphenotypic leukemia. ( 2357699 )
1990
24
Phenotypic conversion of T lymphoblastic lymphoma to acute biphenotypic leukemia composed of lymphoblasts and myeloblasts. Molecular genetic evidence of the same clonal origin. ( 2838522 )
1988
25
Inv(16) occurring in a case of acute biphenotypic leukemia lacking monocytic markers: multiple but short remissions. ( 3470123 )
1987

Variations for Acute Biphenotypic Leukemia

Expression for Acute Biphenotypic Leukemia

Search GEO for disease gene expression data for Acute Biphenotypic Leukemia.

Pathways for Acute Biphenotypic Leukemia

Pathways related to Acute Biphenotypic Leukemia according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 11.22 FLT3 MPO
2 11.05 FLT3 KMT2A MPO
3 10.94 DNTT FLT3

GO Terms for Acute Biphenotypic Leukemia

Sources for Acute Biphenotypic Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....